KEMRI and PCL Inc. Partner on Biotech Innovation
The organizations will collaborate on diagnostic technologies and coffee-derived probiotics to boost local manufacturing.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Should the country prioritize local manufacturing to reduce reliance on imported medical supplies?
The Kenya Medical Research Institute (KEMRI) and South Korean biotech firm PCL Inc. have launched a partnership focused on diagnostic technology and probiotics. This collaboration aims to bolster health security by increasing domestic pharmaceutical production.
Why it matters
These efforts are designed to reduce reliance on imported health products and vaccines. By fostering local manufacturing, the institutions hope to enhance pharmaceutical self-reliance within Kenya.
KEMRI maintains a network of 23 clinical trial sites and is among 15 global participants in the WHO mRNA technology-transfer programme. The partnership focuses on two primary areas: diagnostic technology development and coffee-derived probiotics.
The players
KEMRI
The Kenya Medical Research Institute is a national body that links research, industry, and government to advance medical commercialization.
PCL Inc.
PCL Inc. is a South Korean biotechnology firm that specializes in diagnostic technology.
Prof. Soyoun Kim
Prof. Soyoun Kim is the CEO of PCL Inc. and has been appointed as a visiting professor at KEMRI.
The details
The collaboration links research institutions, industry, and government to facilitate the transition of scientific discoveries from the laboratory to commercial markets. As part of the initiative, KEMRI is developing equipment and technical processes for an mRNA production facility.
Timeline
Prof. Soyoun Kim visited KEMRI between October 7 and October 9, 2026.
The visiting professorship for Prof. Soyoun Kim is set for a three-year term.
The Tech Race
KEMRI currently leverages its position within the WHO and Medicines Patent Pool mRNA technology-transfer programme to modernize domestic production capabilities. This partnership represents a strategic shift toward utilizing international expertise to replace traditional reliance on imported health technologies.
The development of local manufacturing and diagnostic tools aims to improve health security and the availability of essential pharmaceutical products. Residents may eventually see increased local access to medical treatments and advanced diagnostic technology as a result of these initiatives.
The takeaway
International partnerships are increasingly critical for developing nations to establish independent pharmaceutical infrastructure. Expanding domestic manufacturing capabilities is a proven strategy for securing long-term health resilience against global supply chain disruptions.
Further reading
For more updates on medical research, visit the Biotech section.
Source note: This article includes information reported by KEMRI.
Live Poll
Should the country prioritize local manufacturing to reduce reliance on imported medical supplies?
